LitAlert ~~ GeneLit.com

    • The impact of high-intensity interval exercise training on NK-cell function and circulating myokines for breast cancer prevention among women at high risk for breast cancer.
    • Coletta AM, Agha NH, Baker FL, Niemiro GM, Mylabathula PL, Brewster AM, Bevers TB, Fuentes-Mattei E, Basen-Engquist K, Gilchrist SC, Simpson RJ.
    • Breast Cancer Res Treat. 2021 Feb 8. doi: 10.1007/s10549-021-06111-z. Epub ahead of print.
    • An open-label, multi-center, single-arm, phase 2 study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer.
    • Li N, Bu H, Liu J, Zhu J, Zhou Q, Wang L, Yin R, Wu X, Yao S, Gu K, Zhang H, Li G, Pan H, Wu Q, An R, Yang X, Zhu YP, wan X, Duan W, Xiong J, Guo H, Lou G, Wang J, Hu WJ, Zhang X, Meng Y, Zhang B, Wang Y, Wang QR, Wu L.
    • Clin Cancer Res. 2021 Feb 8. doi: 10.1158/1078-0432.CCR-20-3546. Epub ahead of print.
    • Knowledge and perceptions of BRCA1/2 genetic testing and needs of diverse women with a personal or family history of breast cancer in South Florida.
    • Jones T, Howard H, Freeman-Costin K, Creighton A, Wisdom-Chambers K, Underhill-Blazey M.
    • J Community Genet. 2021 Feb 8. doi: 10.1007/s12687-021-00507-6. Epub ahead of print.
    • Abnormal screens among nonmutation carriers in the High Risk Ontario Breast Screening Program.
    • Castelo M, Brown Z, Schellenberg AE, Mills JK, Eisen A, Muradali D, Grunfeld E, Scheer AS.
    • Breast J. 2021 Feb 7. doi: 10.1111/tbj.14185. Epub ahead of print.
    • Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
    • Chiappa M, Guffanti F, Bertoni F, Colombo I, Damia G.
    • Drug Resist Updat. 2021 Jan 16:100744. doi: 10.1016/j.drup.2021.100744. Epub ahead of print.
    • Review